Clinical outcomes of volume of disease on patients receiving enzalutamide versus abiraterone acetate plus prednisone as first-line therapy for metastatic castration-resistant prostate cancer.
Pier Vitale NuzzoFrancesco RaveraCalogero SaievaElisa ZanardiGiuseppe FotiaAndrea MalgeriSabrina RossettiLoana Bueno ValençaThiago Martins OliveiraCharles VauchierRicardo Pereira MestreMikol ModestiAnna PatrikidouSandro PignataGiuseppe ProcopioGiuseppe FornariniUgo De GiorgiAntonio RussoEdoardo FranciniPublished in: Therapeutic advances in medical oncology (2023)
Within the intrinsic limitations of a retrospective design and small population, our report suggests that volume of disease could be a useful predictive biomarker for patients starting first-line ARSi for mCRPC.